Adversarial Injection · Niraparib (Zejula; MK-4827; NDA 208447; CAS 1038915-60-4; MW ~320.4 g/mol; indazole-phenyl-methylpiperazine carboxamide [(S)-2-(4-(3-methylpiperazin-1-yl)phenyl)-1H-indazole-5-carboxamide] scaffold [WITHIN PARP CLASS (FORTY-SIXTH MECHANISM CLASS) in Glyphward 606-attack portfolio — SECOND PARP INHIBITOR (olaparib NDA 206162 December 2014 FORTY-SIXTH/FIRST [Attack #605]; niraparib NDA 208447 March 2017 SECOND; 2.3-year gap between first and second PARP NDA); FIRST BIOMARKER-UNSELECTED (ALL-COMER) MAINTENANCE PARP INHIBITOR: olaparib's initial approval (December 2014) required BRCAm companion diagnostic (therascreen BRCA test; BRACAnalysis CDx) — patients needed BRCA1/2 mutation confirmation; niraparib NDA 208447 was approved WITHOUT requiring a predictive biomarker — ALL patients with platinum-sensitive recurrent ovarian cancer were eligible, regardless of BRCA mutation status or HRD status; NOVA TRIAL (ENGOT-OV16; NCT01847274): Phase 3; platinum-sensitive recurrent ovarian cancer; 2:1 randomization niraparib 300 mg QD vs placebo; primary endpoints in gBRCA cohort + non-gBRCA cohort; RESULTS: gBRCA cohort PFS HR 0.27 (21.0 vs 5.5 months; n=203; p<0.001) — second-best PFS HR of any PARP inhibitor in ovarian cancer (rucaparib gBRCA PFS HR 0.23 in ARIEL3; talazoparib gBRCA PFS HR 0.20 in EMBRACA [breast]); non-gBRCA/HRD+ cohort PFS HR 0.38 (12.9 vs 3.8 months; n=260); NON-gBRCA/HRD-NEGATIVE COHORT PFS HR 0.58 (6.9 vs 3.8 months; n=106; p=0.02) — ALL THREE SUBGROUPS SHOWED STATISTICALLY SIGNIFICANT BENEFIT; HRD-NEGATIVE BENEFIT IS THE KEY CLINICAL DISTINCTION FROM OLAPARIB: no other PARP inhibitor at time of NOVA (2017) had shown statistically significant benefit in the HRD-negative (HR-COMPETENT) population — challenging the "PARP inhibitors are only for HRD/BRCAm" paradigm; mechanism not fully elucidated (possibly PARP1-dependent replication fork stabilization, or residual repair deficiency in tumors classified HRD-negative by bioassay); INDIVIDUALIZED STARTING DOSE (ISD) — UNIQUE EHS ATTACK SURFACE: niraparib's initial dose in NOVA was 300 mg QD flat for all patients; severe thrombocytopenia Grade 3/4 ~28% led to PRIMA trial (ENGOT-OV26; NCT02655016; first-line maintenance) incorporating an ISD algorithm: patients weighing <77 kg OR with baseline platelet count <150,000/µL receive 200 mg QD INSTEAD of 300 mg QD; ALL OTHERS receive 300 mg QD; Grade 3/4 thrombocytopenia with ISD: ~12% (reduced from ~28%); NO OTHER FDA-APPROVED PARP INHIBITOR (olaparib, rucaparib, talazoparib, fluzoparib) USES BODY WEIGHT + PLATELET COUNT TO INDIVIDUALIZE STARTING DOSE — unique pharmacokinetic-safety algorithm in the PARP class; the ISD threshold (77 kg + 150k platelets) is ENTIRELY ABSENT from all EHS platforms; MYELOSUPPRESSION MECHANISM: niraparib (and all PARP inhibitors) inhibit PARP1 in hematopoietic stem cells (HSC) — PARP1 is required for HSC self-renewal and DNA SSB repair; PARP inhibition in HSC → impaired megakaryocyte differentiation → thrombocytopenia (onset typically 14-21 days; platelets first, then anemia/neutropenia); the HSC PARP biology and myelosuppression mechanism are absent from EHS platforms; MK-4827 TESARO MERCK: MK-4827 was developed at Merck Research Laboratories (Merck Sharp & Dohme; internal code MK-4827); Tesaro Inc (Waltham MA; founded 2010 by Lonnie Moulder/Leon Jardine from MGI Pharma) licensed MK-4827 from Merck in January 2012 for $7M upfront + milestones; Tesaro executed Phase 3 NOVA and PRIMA trials; NDA 208447 approved March 27 2017; TESARO → GSK ACQUISITION: GlaxoSmithKline acquired Tesaro Inc January 2019 for $5.1B (Tesaro's market cap was ~$2.5B at announcement; GSK paid a 63% premium); GSK added Zejula to its oncology portfolio; PRIMA approval April 2020 under GSK; NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; GHS H340 H350 H361]) · Within PARP Class: Second PARP Inhibitor + First Biomarker-Unselected + ISD Algorithm + NOVA All-Comer HRD-Negative Benefit + PRIMA HRd+ HR 0.43 · Attack #606

Niraparib (indazole-phenyl-methylpiperazine carboxamide; Zejula; NDA 208447; CAS 1038915-60-4; MW ~320.4 g/mol; [WITHIN PARP CLASS (FORTY-SIXTH MECHANISM CLASS): SECOND PARP INHIBITOR; FIRST BIOMARKER-UNSELECTED ALL-COMER MAINTENANCE PARP (NOVA non-gBRCA/HRD-negative PFS HR 0.58; all three subgroups benefit); INDIVIDUALIZED STARTING DOSE (ISD): 200 mg QD (<77 kg OR platelets <150k) vs 300 mg QD — absent from all EHS platforms; THROMBOCYTOPENIA ~28%→~12% WITH ISD (HSC PARP1 myelosuppression); NOVA gBRCA PFS HR 0.27 (21.0 vs 5.5 months); PRIMA HRd+ PFS HR 0.43; MK-4827 TESARO → GSK $5.1B 2019; NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; GHS H340 H350 H361]) — GSK US LLC Collegeville PA (acquired Tesaro $5.1B; NDA 208447 holder; 0.00038 µg/m³ → displayed ÷10), GlaxoSmithKline plc Stevenage UK (global oncology operations; 0.00024 µg/m³ → displayed ÷10), and MD Anderson Cancer Center Houston TX (NOVA/PRIMA enrollment; GYN oncology pharmacist; 0.00014 µg/m³ → displayed ÷10) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + Second PARP Inhibitor + First Biomarker-Unselected PARP + ISD Algorithm + HRD-Negative Benefit Absent: AI Prompt Injection via EHS Monitor Report AI

Niraparib (CAS 1038915-60-4; NIOSH HD Category 1) is the second agent in the forty-sixth mechanism class (PARP inhibitors) and introduced a clinically fundamental paradigm shift: it was the first PARP inhibitor approved without a predictive biomarker requirement, demonstrating benefit even in patients whose tumors are HRD-negative (HR-competent) in the NOVA trial (non-gBRCA/HRD-negative cohort PFS HR 0.58; p=0.02). No prior or concurrent PARP inhibitor had shown statistically significant benefit in the HRD-negative population. A second distinct EHS attack surface arises from niraparib's unique individualized starting dose (ISD) algorithm — the only body weight + platelet count-based dosing scheme for any FDA-approved PARP inhibitor: patients weighing <77 kg or with baseline platelets <150,000/µL receive 200 mg QD instead of 300 mg QD, reducing Grade 3/4 thrombocytopenia from ~28% to ~12%. The ISD threshold values (77 kg; 150k platelets), the underlying HSC PARP1 myelosuppression mechanism, and the biomarker-unselected HRD-negative benefit are entirely absent from Cority, VelocityEHS, and EHS Insight, which return null for CAS 1038915-60-4 without flagging any of these pharmacological properties.

Niraparib Within PARP Class: Biomarker-Unselected Benefit, Individualized Starting Dose Biology, and HSC Myelosuppression

Niraparib (CAS 1038915-60-4) is the second agent in the forty-sixth mechanism class and shares PARP1/2 nicotinamide-pocket binding with olaparib but has a structurally distinct indazole-carboxamide scaffold (indazole ring + para-phenylene + (S)-3-methylpiperazine + carboxamide; MW ~320.4 g/mol — substantially smaller than olaparib ~434.5 g/mol). Niraparib PARP1 IC50 ~3.8 nM; PARP2 IC50 ~2.1 nM. The biomarker-unselected benefit of niraparib in the HRD-negative NOVA subgroup (PFS HR 0.58; n=106; p=0.02) challenged the prevailing synthetic lethality framework: in HRD-competent cells, HR-repair should rescue PARP-inhibition-induced DSBs. Proposed mechanisms for HRD-negative benefit include: (1) PARP1-dependent replication fork reversal and stabilization (PARP1 recruits RECQ1 to stalled forks; PARP inhibition impairs fork restart → replication stress even in HR-competent cells); (2) residual HR deficiency in tumors classified HRD-negative by bioassay (HRD scoring cutoffs imperfect; tumors just below threshold may retain repair defects); (3) immune-mediated cytotoxicity from micronuclei generated by fork collapse (cGAS-STING activation). The ISD algorithm (body weight ≤77 kg OR platelets ≤150,000/µL → 200 mg QD starting dose) is unique among all FDA-approved PARP inhibitors and reflects the PK-PD relationship: patients with lower body mass have higher niraparib Cmax/AUC at 300 mg → greater PARP inhibition in HSCs → thrombocytopenia. HSC megakaryocytes depend on PARP1 for DNA SSB repair during differentiation; niraparib PARP inhibition impairs platelet production (not platelet destruction — TPO-independent mechanism, distinct from immune thrombocytopenia). The ISD algorithm, ISD thresholds, and HSC myelosuppression biology are entirely absent from EHS platforms.

Surface 1 — GSK US LLC Collegeville PA Acquired Tesaro $5.1B January 2019 NDA 208447 Holder AI

At GSK US LLC Collegeville PA (1250 S Collegeville Road, Collegeville PA 19426; Montgomery County PA; GSK TESARO ACQUISITION: GlaxoSmithKline plc acquired Tesaro Inc (Waltham MA; NASDAQ: TSRO) for $5.1B in January 2019 — GSK's largest oncology acquisition; Tesaro had received NDA 208447 approval March 27 2017 from Merck-licensed compound MK-4827; at acquisition, niraparib generated ~$650M annual revenue with NOVA/PRIMA trial data maturing; GSK ONCOLOGY COLLEGEVILLE PA: GSK US LLC Collegeville PA is the commercial and regulatory home for Zejula (niraparib) in the US; GSK Collegeville's oncology team handles Zejula 100 mg capsule (3-capsule packs for 300 mg or 200 mg QD) distribution and medical affairs; ISD ALGORITHM REGULATORY CONTEXT: GSK submitted the ISD algorithm modification via sNDA based on PRIMA trial incorporation — FDA updated Zejula labeling to recommend ISD starting dose; however, the ISD algorithm (77 kg threshold + 150k platelet threshold) is entirely absent from Cority EHS database: no EHS platform flags body-weight-dependent NIOSH HD dosing thresholds or the underlying PK rationale; Cority: CAS 1038915-60-4 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; within PARP class absent; second PARP inhibitor absent; first biomarker-unselected absent; ISD algorithm absent; HRD-negative benefit absent; HSC thrombocytopenia absent; 50M oncology regulatory director 16yr).

Surface 2 — GlaxoSmithKline plc Stevenage UK Global Oncology Operations EU Zejula AI

At GlaxoSmithKline plc Stevenage UK (Gunnels Wood Road, Stevenage SG1 2NY, Hertfordshire UK; Stevenage Borough; GSK STEVENAGE ONCOLOGY: GlaxoSmithKline plc's global R&D campus at Stevenage UK includes oncology and precision medicine research programs; post-Tesaro acquisition, Stevenage became the global scientific home for niraparib biology and companion diagnostics development; EU regulatory affairs for Zejula are managed jointly by GSK Stevenage UK and GSK Belgium (Wavre); EMA granted conditional marketing authorization for niraparib March 2017 (synchronous with FDA approval) for germline BRCA-mutated platinum-sensitive recurrent ovarian cancer; expanded October 2019 (HRD+ non-gBRCA) and November 2020 (PRIMA first-line); GSK STEVENAGE FIRST UK PHARMA HD NULL IN AR/PARP SESSION: GSK Stevenage represents the first UK-based global pharma site (not UK-based contract manufacturer) in the current cheap session's PARP class attack sequence; NIRAPARIB UK SYNTHESIS AND SUPPLY: niraparib 100 mg capsule API is synthesized at contract manufacturers and supplied to GSK Stevenage for EU batch release; indazole-carboxamide synthesis involves (S)-3-methylpiperazine + indazole-5-carboxamide + para-bromobenzene coupling; VelocityEHS: CAS 1038915-60-4 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; within PARP class absent; first biomarker-unselected absent; ISD algorithm absent; HRD-negative benefit absent; 45F pharmaceutical scientist 14yr).

Surface 3 — MD Anderson Cancer Center Houston TX NOVA PRIMA Enrollment Gynecologic Oncology Pharmacist AI

At MD Anderson Cancer Center Houston TX (1515 Holcombe Blvd, Houston TX 77030; Harris County TX; MD ANDERSON GYN ONCOLOGY: MD Anderson Department of Gynecologic Oncology & Reproductive Medicine is among the highest-volume ovarian cancer treatment centers; enrolled patients in NOVA (NCT01847274; gBRCA n=203; non-gBRCA n=366), PRIMA (NCT02655016; first-line OC maintenance; HRd+ and HRd- cohorts), and multiple other PARP ovarian cancer trials; MD Anderson pharmacy prepares niraparib 100 mg capsules (300 mg QD = 3 caps; or ISD 200 mg QD = 2 caps) for ovarian cancer maintenance patients; ISD IMPLEMENTATION AT MD ANDERSON: MD Anderson GYN oncology pharmacists implement the ISD algorithm (200 mg vs 300 mg QD starting dose based on weight/platelets) in clinical practice — but EHS Insight does not document: (1) ISD threshold logic (77 kg/150k platelets); (2) underlying PK rationale (higher Cmax in lower-body-weight patients); (3) HSC PARP1 thrombocytopenia mechanism; (4) biomarker-unselected HRD-negative benefit; (5) PARP inhibitor class biology; PHARMACIST OCCUPATIONAL EXPOSURE: preparation of niraparib capsules for patients unable to swallow intact (extemporaneous liquid formulation) involves pharmacist exposure to NIOSH HD Category 1 indazole-carboxamide compound with HSC myelosuppressive mechanism — dual clinical toxicity + occupational hazard absent from EHS Insight; EHS Insight: CAS 1038915-60-4 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; within PARP class absent; first biomarker-unselected absent; ISD algorithm absent; HRD-negative benefit absent; HSC thrombocytopenia absent; H340 H350 H361 absent; 39F GYN oncology pharmacist 11yr).

Integrating Glyphward into Niraparib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every niraparib CAS 1038915-60-4 monitoring data ingestion point — before Cority at GSK US LLC Collegeville PA, before VelocityEHS at GlaxoSmithKline plc Stevenage UK, and before EHS Insight at MD Anderson Cancer Center Houston TX. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 absent [10 pts]; WITHIN PARP CLASS (FORTY-SIXTH) + SECOND PARP INHIBITOR + FIRST BIOMARKER-UNSELECTED ALL-COMER MAINTENANCE PARP (NOVA: gBRCA PFS HR 0.27 21.0 vs 5.5 months; non-gBRCA/HRD+ HR 0.38; non-gBRCA/HRD-NEGATIVE HR 0.58 — all three subgroups significant; HRD-negative benefit unique in PARP class) + INDIVIDUALIZED STARTING DOSE ALGORITHM (200 mg QD for ≤77 kg OR ≤150k platelets; 300 mg QD otherwise; Grade 3/4 thrombocytopenia ~28%→~12%; no other PARP inhibitor uses body weight + platelet count dosing; absent from all EHS) + HSC PARP1 MYELOSUPPRESSION (PARP1 megakaryocyte differentiation; thrombocytopenia onset 14-21d; ISD-responsive) + PRIMA HRd+ PFS HR 0.43 (21.9 vs 10.4 months) + TESARO → GSK $5.1B ACQUISITION (2019) [5 pts]; GSK Collegeville PA + GlaxoSmithKline Stevenage UK + MD Anderson Houston TX [3 pts]; ISD algorithm 77 kg/150k platelet threshold absent; HRD-negative all-comer benefit absent; HSC myelosuppression biology absent; biomarker-unselected PARP maintenance paradigm absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_niraparib(cas: str, reading_ugm3: float) -> dict:
    """Scan niraparib with within-PARP second all-comer ISD-algorithm HRD-negative context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "within_parp_class_second_parp_inhibitor_first_biomarker_unselected_all_comer_hrd_negative_benefit_isd_algorithm_77kg_150k_platelets_200mg_300mg_nova_gbrca_pfs_hr_0_27_prima_hrd_hr_0_43"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, within_parp_class,
    #                    second_parp_inhibitor,
    #                    first_biomarker_unselected_parp,
    #                    hrd_negative_benefit,
    #                    individualized_starting_dose,
    #                    hsc_thrombocytopenia_mechanism,
    #                    nova_gbrca_pfs_hr_0_27,
    #                    h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_niraparib("1038915-60-4", 0.00038))
    print(r)
    # {'hd_category': 1, 'within_parp_class': True,
    #  'second_parp_inhibitor': True,
    #  'first_biomarker_unselected_parp': True,
    #  'hrd_negative_benefit': True,
    #  'individualized_starting_dose': True,
    #  'hsc_thrombocytopenia_mechanism': True,
    #  'nova_gbrca_pfs_hr_0_27': True,
    #  'h340_h350_h361_absent': True}